More recent work using small-interfering peptides (SiPs) that selectively block Cdk5-p25 but not Cdk5-p35 interactions by both pharmacological and transgenic means has shown promise in preclinical models of neurodegeneration and stroke (Binukumar et al., 2015; Binukumar and Pant, 2016). The gene discussed is CDK5; the disease is Stroke.